Comparable recurrence risk for <scp>MRI</scp> ‐detected Gleason Grade Group (GG) <scp>2</scp> and systematic biopsy‐detected <scp>GG1</scp> prostate cancer
Men diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.
Authors
- Joona Pohjonen (ORCID: https://orcid.org/0000-0001-8783-4793)
- Andrew M. Erickson (ORCID: https://orcid.org/0000-0002-4850-4086)
- Abderrahim-Oussama Batouche (ORCID: https://orcid.org/0000-0003-4181-9891)
- Antti Rannikko (ORCID: https://orcid.org/0000-0002-4261-3484)
- Tuomas Mirtti (ORCID: https://orcid.org/0000-0003-0455-9891)
- Timo‐Pekka Lehto (ORCID: https://orcid.org/0000-0003-3262-2333)
- Teemu D. Laajala (ORCID: https://orcid.org/0000-0002-7016-7354)
- Eugen Czeizler (ORCID: https://orcid.org/0000-0002-1607-1554)
- Tolou Shadbahr (ORCID: https://orcid.org/0000-0001-5715-5933)
Institutions
- University of Helsinki (FI)
- Emory University (US)
- Helsinki University Hospital (FI)
- University of Oxford (GB)
- Cancer Society of Finland (FI)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1111/bju.70109
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Helsingin Yliopisto
- Jane ja Aatos Erkon Säätiö